Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 129

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 129
---
 which includes 45,141 
 shares of Common Stock reserved for issuance under our 2016 Plan and our 2024 Plan;          |

| ● | 5,272                                                                                        
 shares of Common Stock issuable under our 2024 ESPP, which includes 527,182 shares of Common 
 Stock reserved for issuance under our 2024 ESPP;                                             |

| ● | 95,175                                                                                     
 shares of Common Stock issuable upon the exercise of Public Warrants and Private Placement 
 Warrants;                                                                                  |

| ● | 87,879                                                                                       
 shares of Common Stock issuable upon the exercise of Common Warrants issued in the offerings 
 of our Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock; and  |

| ● | 1,345,679                                                                                 
 shares of Common Stock issuable upon conversion of the Series A Preferred Stock, Series B 
 Preferred Stock, and Series C Preferred Stock, including 497,977 shares issuable upon the 
 exercise of Preferred Warrants.                                                           |

To the extent any outstanding options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional equity or convertible securities in the future, there will be further dilution to new investors participating in this offering. 73 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION PBAX, and after the Business Combination, CERo, is providing the following unaudited pro forma condensed combined financial information to aid you in your analysis of the financial aspects of the Business Combination and related transactions. The following unaudited pro forma condensed financial information presents the combination of the financial information of PBAX and Legacy CERo adjusted to give effect to the Business Combination and related transactions. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation S-X as amended by the final rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses.” The historical financial information of PBAX was derived from the audited financial statements of PBAX for the year ended December 31, 2023. The historical financial information of Legacy CERo was derived from audited financial statements of Legacy CERo for the year ended December 31, 2023. Such unaudited pro forma financial information has been prepared on a basis consistent with the audited financial statements of PBAX and Legacy CERo, respectively, and should